Articles from MorphoSys AG

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”).

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG and Novartis AG hereinafter collectively referred to as “Novartis”) also informed MorphoSys of their intention to merge MorphoSys into Novartis by initiating a squeeze-out of MorphoSys’ minority shareholders.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.

The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total equity value of € 2.7 billion (the “Takeover Offer”). The offer price corresponds to a premium of 94% and 142% on the volume-weighted average price during the last month and three months, respectively, as of the unaffected January 25, 2024, closing price.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced strong topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the third quarter and the first nine months of 2023.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the second quarter and first half year of 2023.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2023.

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2022.

Conference call and webcast (in English) tomorrow, November 17, 2022, at 2:00pm CET (1pm GMT/8:00am ET)

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Malte Peters, M.D., the company’s Chief Research and Development Officer and Management Board member, has decided to retire at the end of 2022. His successor will be Tim Demuth, M.D., Ph.D., current Chief Medical Officer of Pieris Pharmaceuticals, Inc., a clinical-stage biotechnology company. Tim will start his new role on October 1. He will report to MorphoSys’ CEO, Jean-Paul Kress, M.D., and be a member of the company’s Executive Committee. At this time, Malte will step down from his operational responsibilities.

Conference call and webcast (in English) tomorrow, August 4, 2022, at 2:00pm CEST (1pm BST/8:00am EDT)

Conference Call Alert

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQMOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022 and announced an update of its financial guidance for 2022 based on the preliminary unaudited consolidated results for the first six months 2022 and following the license agreements with Human Immunology Biosciences, Inc. (HIBio) for felzartamab and MOR210.

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014

MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), a South San Francisco-based biotechnology company focused on discovering and developing precision medicines for autoimmune and inflammatory diseases, announced today that the companies entered into an equity participation agreement and license agreements to allow HIBio to develop and commercialize MorphoSys’ felzartamab, an anti-CD38 antibody, and MOR210, an anti-C5aR1 antibody.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQMOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place on Wednesday, May 18, 2022, including:

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter 2022.

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Minjuvi is a new therapeutic option for eligible DLBCL patients in Switzerland addressing an urgent unmet medical need - In Switzerland each year approximately 500 patients are diagnosed with relapsed or refractory DLBCL[1] PLANEGG and

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021.

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQMOR), announced today that the National Comprehensive Cancer Network(R) (NCCN) Clinical Practice Guidelines (NCCN Guidelines(R)) in Oncology for B-cell Lymphomas have been updated, and the designation for Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide is now a Preferred Regimen for second-line therapy in

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR);(NASDAQMOR) will publish its results for the financial year 2021 on March 16, 2022 at 9:00 pm CET (8:00 pm GMT; 4:00 pm EDT). MorphoSys' Management team will host a conference call and webcast on March 17, 2022 at 1:00 pm CET (12:00 pm GMT; 8:00 am EDT) to present results for the financial year 2021 and provide an outlook for 2022. The

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 10, 2022 / MorphoSys AG (FSE:MOR) (NASDAQMOR) announces today that it will account for a non-cash impairment charge on goodwill in the amount of approximately € 231 million. This write-down results from the consolidation of the Company's research and discovery activities after the

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 24, 2022 / MorphoSys AG (FSE:MOR)(NASDAQMOR) was acknowledged as a Best Practice Leader in the European Women on Boards' Gender Equality Index Report, ranking number one in Germany and number two among European healthcare companies for female representation at the leadership level and in decision-making positions. The European Women on Boards Gender Equality Index Report assessed 668 European

- Preliminary 2021 Monjuvi U.S. net product sales of US$ 79.1 million ( € 66.9 million) - Anticipated 2022 Monjuvi U.S. net product sales in the range of US$ 110 to 135 million PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 18, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) today reported preliminary Monjuvi (R) U.S. net product sales for the full year of 2021 and provided financial guidance for 2022. Preliminary Monjuvi (tafasitamab-cxix)

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / Janauary 10, 2022 / MorphoSys AG (FSE:MOR; NASDAQ:MOR), announced today that Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, will present at the 40 th Annual J.P. Morgan Healthcare Conference on Wednesday January 12, 2022 at 5:15 p.m. EST. Live audio of the presentation can be accessed from the Investors section under Conferences, Webcast & Presentations on MorphoSys' website,

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis - Data presented during poster and oral sessions at the 63rd American Society of Hematology Annual Meeting and Exposition - Latest results from the MANIFEST trial underscore the rationale to further explore pelabresib in combination with ruxolitinib in MANIFEST-2, a global, Phase 3, randomized, double-blind

- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate significant overall survival improvement compared with Pola-BR and R2 BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / December 11, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQMOR), and Incyte NASDAQ:INCYNASDAQINCY)

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement / Report Conference Call Year-End Results 2021 March 16, 2022 // 10 pm CET (5 pm EDT; 9 pm GMT) March 17, 2022 // 2 pm CET (9 am EDT; 1 pm GMT) First Quarter Interim Statement 2022 May 4, 2022 // 10 pm CEST (4 pm EDT; 9 pm BST) May 5, 2022

- Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q - Ten abstracts, including two oral presentations, accepted at upcoming ASH - Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data - Felzartamab demonstrated proof-of-concept in patients with aMN at Kidney Week PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 11, 2021 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer (COO) and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities. Following Dr. Wandeler's departure, the commercial organization led by Joe Horvat, U.S. General Manager, will report directly to the

Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN) on November 4-7. The poster entitled "Felzartamab in patients with

- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational data - MANIFEST update on pelabresib monotherapy in patients with myelofibrosis - Expanded Real-World RE-MIND2 dataset comparing outcomes for tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T in relapsed/refractory diffuse large

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQMOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to € 18.6 million (US$ 22 million) for the third quarter of 2021 and € 46.4 million (US$ 55.5 million) for the first nine months of 2021. Monjuvi (R) is being co-commercialized by Incyte and MorphoSys in the United States. MorphoSys will

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN). IgAN, also known as Berger's disease, is a chronic and debilitating autoimmune disease affecting the kidneys and the most common glomerular disease worldwide. Currently there are no

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, for the treatment of people living with Alzheimer's disease (AD). This designation is based on data showing that gantenerumab

-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (EU), addressing an urgent unmet medical need - In Europe, each year approximately 16,000 patients are diagnosed with relapsed or refractory

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and license agreement with a subsidiary of InnoCare for tafasitamab in Greater China. Under the terms of the agreement, InnoCare will receive the rights to develop and exclusively commercialize tafasitamab, a humanized Fc-modified

- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Pharma - Updated group financial guidance - Conference call and webcast (in English) tomorrow, July 29, 2021, at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announces today an update of its financial guidance for 2021 after preliminary completion of the latest evaluation of MorphoSys' half year 2021 financial performance. Based on the preliminary unaudited consolidated results for the first six months 2021,

PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT). MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second

PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQMOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issuing 1,337,552 new ordinary shares from the Authorized Capital 2021-II, excluding pre-emptive rights of existing shareholders, to implement the purchase of 1,337,552 new ordinary shares by

Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQCNST) ("Constellation") for $34.00 per share, net to

MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQMOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation Pharmaceuticals, Inc., NASDAQ:CNSTNASDAQCNST)

- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / June 25, 2021 / MorphoSys

PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) ("Constellation") for $34.00 per share, net to the seller in cash, without interest, and subject to any applicable withholding of taxes. The tender offer is being made pursuant to the previously announced merger

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (NASDAQMOR), and Incyte NASDAQ:INCYNASDAQINCY)

MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQMOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation Pharmaceuticals, Inc. NASDAQ: CNSTNASDAQCNST)

MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”), and Constellation Pharmaceuticals, Inc., (NASDAQCNST) (“Constellation”) today announced that they have entered into a definitive agreement whereby MorphoSys will acquire Constellation for $34.00 per share in cash, which represents a total equity value of $1.7 billion. The transaction has been unanimously approved by the management board (Vorstand) and the supervisory board (Aufsichtsrat) of MorphoSys, as well as the Board of Directors of Constellation and is expected to close in the third quarter of 2021.

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. Eastern Time. Live audio of the fireside chat can be accessed from the Media and Investors section under Conferences on MorphoSys' website,

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, which was approved as Monjuvi(R) (tafasitamab-cxix) in July 2020 by

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR) and Incyte NASDAQ:INCYNASDAQINCY)

- MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) - Tremfya royalties of € 11.6 million - Reaffirming group revenue guidance of € 150 to € 200 million - Conference call and webcast (in English) tomorrow, May 6, 2021 at 2:00pm CEST (1:00pm BST/8:00am EDT) PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 5, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR)

Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQMOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST (4:00pm EDT). MorphoSys' Management Board will host

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQINCY) today announced the first patient has been dosed in the placebo-controlled Phase 3 inMIND study evaluating the efficacy and safety of tafasitamab or placebo in combination with lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL) or